CY1116405T1 - Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης - Google Patents

Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης

Info

Publication number
CY1116405T1
CY1116405T1 CY20151100518T CY151100518T CY1116405T1 CY 1116405 T1 CY1116405 T1 CY 1116405T1 CY 20151100518 T CY20151100518 T CY 20151100518T CY 151100518 T CY151100518 T CY 151100518T CY 1116405 T1 CY1116405 T1 CY 1116405T1
Authority
CY
Cyprus
Prior art keywords
formula
coa
acetylo
lactamic
inactions
Prior art date
Application number
CY20151100518T
Other languages
Greek (el)
English (en)
Inventor
Scott William Bagley
Robert Lee Dow
David Andrew Griffith
Aaron Christopher Smith
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1116405T1 publication Critical patent/CY1116405T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
CY20151100518T 2010-10-29 2015-06-12 Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης CY1116405T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US201161531744P 2011-09-07 2011-09-07
EP11784783.0A EP2632925B1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1116405T1 true CY1116405T1 (el) 2017-02-08

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100518T CY1116405T1 (el) 2010-10-29 2015-06-12 Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης

Country Status (26)

Country Link
US (3) US8859773B2 (OSRAM)
EP (2) EP2632925B1 (OSRAM)
JP (2) JP5647356B2 (OSRAM)
KR (2) KR20150006899A (OSRAM)
CN (2) CN103189377B (OSRAM)
AR (1) AR083578A1 (OSRAM)
AU (1) AU2011322117B2 (OSRAM)
BR (1) BR112013010310A2 (OSRAM)
CA (1) CA2815169C (OSRAM)
CY (1) CY1116405T1 (OSRAM)
DK (1) DK2632925T3 (OSRAM)
ES (1) ES2546465T3 (OSRAM)
HK (1) HK1209733A1 (OSRAM)
HU (1) HUE025078T2 (OSRAM)
IL (1) IL225779A0 (OSRAM)
MX (1) MX2013004733A (OSRAM)
NZ (1) NZ609527A (OSRAM)
PL (1) PL2632925T3 (OSRAM)
PT (1) PT2632925E (OSRAM)
RU (1) RU2540337C2 (OSRAM)
SG (1) SG189883A1 (OSRAM)
SI (1) SI2632925T1 (OSRAM)
TW (3) TWI507406B (OSRAM)
UY (1) UY33694A (OSRAM)
WO (1) WO2012056372A1 (OSRAM)
ZA (1) ZA201303882B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815169C (en) * 2010-10-29 2015-10-06 Pfizer Inc. N1/n2-lactam acetyl-coa carboxylase inhibitors
JP6321042B2 (ja) 2013-02-06 2018-05-09 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なハロゲン置換された化合物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
US10273226B2 (en) 2014-01-03 2019-04-30 Bayer Animal Health Gmbh Pyrazolyl-heteroarylamides as pesticides
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
AU2016231174B2 (en) 2015-03-10 2020-09-10 Bayer Animal Health Gmbh Pyrazolyl-derivatives as pest control agents
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
BR112019017108A2 (pt) 2017-03-16 2020-04-07 Jiangsu Hengrui Medicine Co derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
AU2018236290B2 (en) 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
RU2020116458A (ru) 2017-11-21 2021-12-23 Пфайзер Инк. Кристаллическая соль 2-амино-2-(гидроксиметил)пропан-1,3-диола и 4-(4-(1-изопропил-7-оксо-1,4,6,7-тетрагидроспиро[индазол-5,4ʼ-пиперидин]-1ʼ-карбонил)-6-метоксипиридин-2-ил)бензойной кислоты
EP3826722A1 (en) 2018-07-24 2021-06-02 F. Hoffmann-La Roche AG Isoquinoline compounds and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
US12428397B2 (en) 2020-05-12 2025-09-30 Merck Sharp & Dohme Llc Factor XI activation inhibitors
JPWO2021235508A1 (OSRAM) * 2020-05-21 2021-11-25
US12049470B2 (en) 2021-02-01 2024-07-30 Celgene Corporation MK2 inhibitors, the synthesis thereof, and intermediates thereto
EP4358948A4 (en) * 2021-06-25 2025-05-14 Cedilla Therapeutics, Inc. TEAD INHIBITORS AND USES THEREOF
WO2024023727A1 (en) * 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
TW202530207A (zh) * 2023-08-16 2025-08-01 智擎生技製藥股份有限公司 Mta協同性的prmt5抑制劑
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (OSRAM) * 1970-05-22 1974-07-02
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP2005504059A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール7−アザ[2.2.1]ビシクロヘプタン
BR0307874A (pt) 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
HRP20090471T1 (hr) 2004-05-12 2009-10-31 Pfizer Products Inc. Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7935712B2 (en) 2005-07-19 2011-05-03 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
AP2009004880A0 (en) 2006-11-29 2009-06-30 Pfizer Prod Inc Spiroketone acetyl-COA carboxylase inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2008125945A2 (en) 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8318762B2 (en) * 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
CA2730493A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
WO2010013161A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
EP2604604A1 (en) 2009-03-11 2013-06-19 Pfizer Inc Benzofuranyl derivatives used as glucokinase inhibitors
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク 3−オキサ−7−アザビシクロ[3.3.1]ノナン
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
CA2759891A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
WO2010140092A1 (en) 2009-06-05 2010-12-09 Pfizer Inc. L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
US20120225900A1 (en) * 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CU24077B1 (es) * 2009-11-10 2015-03-30 Pfizer DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
CA2815169C (en) * 2010-10-29 2015-10-06 Pfizer Inc. N1/n2-lactam acetyl-coa carboxylase inhibitors

Also Published As

Publication number Publication date
AU2011322117B2 (en) 2015-01-22
EP2632925A1 (en) 2013-09-04
UY33694A (es) 2012-05-31
JP2015057416A (ja) 2015-03-26
CN103189377B (zh) 2015-02-25
RU2013116924A (ru) 2014-12-10
KR20140014078A (ko) 2014-02-05
PL2632925T3 (pl) 2015-10-30
HK1186724A1 (en) 2014-03-21
TW201418256A (zh) 2014-05-16
DK2632925T3 (en) 2015-06-29
WO2012056372A1 (en) 2012-05-03
BR112013010310A2 (pt) 2016-11-29
CN103189377A (zh) 2013-07-03
MX2013004733A (es) 2013-07-02
US20150152109A1 (en) 2015-06-04
US8993586B2 (en) 2015-03-31
SG189883A1 (en) 2013-06-28
JP5647356B2 (ja) 2014-12-24
ZA201303882B (en) 2014-02-26
KR20150006899A (ko) 2015-01-19
NZ609527A (en) 2014-03-28
EP2952514A1 (en) 2015-12-09
CA2815169C (en) 2015-10-06
US9181252B2 (en) 2015-11-10
TWI441823B (zh) 2014-06-21
US8859773B2 (en) 2014-10-14
CA2815169A1 (en) 2012-05-03
CN104774205A (zh) 2015-07-15
TWI507406B (zh) 2015-11-11
TW201302751A (zh) 2013-01-16
HK1209733A1 (en) 2016-04-08
HUE025078T2 (en) 2016-01-28
AR083578A1 (es) 2013-03-06
SI2632925T1 (sl) 2015-07-31
US20120108619A1 (en) 2012-05-03
EP2632925B1 (en) 2015-05-27
PT2632925E (pt) 2015-09-01
JP2013542218A (ja) 2013-11-21
ES2546465T3 (es) 2015-09-23
AU2011322117A1 (en) 2013-05-02
KR101529404B1 (ko) 2015-06-26
TW201531472A (zh) 2015-08-16
US20150025098A1 (en) 2015-01-22
IL225779A0 (en) 2013-06-27
RU2540337C2 (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1123702T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1123569T1 (el) Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1119530T1 (el) Συνθεσεις και μεθοδοι ρυθμισης toy fxr
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης